Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A tailored in vivo CRISPR screen identifies BAP1 as a potent tumor suppressor of sarcoma.

JCI insight·2026
Same author

Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC).

Oncoimmunology·2026
Same author

Tumor microenvironment remodeling by STING agonism sensitizes endothelial cells to cytotoxic anti-PD-L1/L2 antibody.

Journal of experimental & clinical cancer research : CR·2026
Same author

IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer.

Scientific reports·2026
Same author

Bright side of the dark genome: antigens for next-gen cancer vaccines.

Journal for immunotherapy of cancer·2026
Same author

Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer.

NPJ breast cancer·2026

Related Experiment Video

Updated: Apr 1, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Editorial: Advances in Combination Tumor Immunotherapy

Michael A Curran1, Bernard A Fox2, William L Redmond2

  • 1Department of Immunology, UT MD Anderson Cancer Center , Houston, TX , USA.

Frontiers in Oncology
|October 7, 2015
PubMed
Summary

No abstract available in PubMed .

Keywords:
4-1BBOX40checkpoint blockadecombination therapyimmunotherapy

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K
Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
08:02

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

Published on: March 6, 2012

17.1K

Related Experiment Videos

Last Updated: Apr 1, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K
Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
08:02

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

Published on: March 6, 2012

17.1K